Cullinan Therapeutics, Inc. (CGEM) Latest Stock News & Headlines ...
Get the latest Cullinan Therapeutics, Inc. (CGEM) stock news and headlines to help you in your trading and investing decisions.
Cullinan Therapeutics | Modality-Agnostic Targeted Therapeutics
Read the latest news and information from Cullinan Therapeutics. Collaboration is key to how we work at Cullinan Therapeutics. The closer we work together—across teams, programs, backgrounds, and experiences—the better we can challenge the status quo.
Cullinan Therapeutics' CLN-978 And Zipalertinib Look Promising …
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) is a biotech that develops autoimmune diseases and oncology therapies.CGEM’s investigational drug CLN-978 is designed to kill pathogenic B cells in ...
Cullinan Therapeutics Receives U.S. FDA Clearance of …
CLN-978 is a novel, highly potent CD19xCD3 bispecific T cell engager. CLN-978 triggers redirected lysis of CD19-expressing target cells in vitro and in vivo. CLN-978 is engineered to achieve...
Cullinan Therapeutics Announces Strategic Expansion into …
Apr 16, 2024 · Cullinan Therapeutics intends to pursue development of CLN-978 in autoimmune diseases, with systemic lupus erythematosus (SLE) as a first indication.
Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote
Find the latest Cullinan Therapeutics, Inc. (CGEM) stock quote, history, news and other vital information to help you with your stock trading and investing.
Cullinan Therapeutics Receives U.S. FDA Clearance of …
Oct 16, 2024 · CLN-978 is a novel, highly potent CD19xCD3 bispecific T cell engager. CLN-978 triggers redirected lysis of CD19-expressing target cells in vitro and in vivo. CLN-978 is engineered to achieve...
Cullinan News - Facebook
People of Local Townships including the surroundings get to socialise and share life experiences together as well as selling their services to others.
Cullinan Therapeutics: Casting A Wide Net With Their Pipeline
Cullinan Therapeutics is a multifocal biotech with promising programs in precision medicine and immunotherapy, despite recent market sentiment declines. Zipalertinib shows potential in treating ...
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 5.4
3 days ago · On average, analysts forecast that Cullinan Therapeutics, Inc. will post -3.12 earnings per share for the current year. Insiders Place Their Bets. In other news, insider Jennifer Michaelson sold 8,000 shares of the company's stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $15.64, for a total ...